Global Hemophilia A and B Drug Forecast and Market Analysis Report 2021-2030 – Gene Therapies and Alternative Modulators of the Coagulation Cascade Remain the Main R&D Focus – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hemophilia A and B – Global Drug Forecast and Market Analysis to 2030” report has been added to ResearchAndMarkets.com’s offering.

Hemophilia A and B Market Is Expected to Grow to $14.71B by 2030.

The current market leader is Roche’s Hemlibra however, BioMarin’s gene therapy Roctavian is expected to be the market leader at the end of the forecast period.

The global market is expected to experience growth during the forecast period. Eleven agents are forecast to launch in the forecast period in the 8MM; four gene therapies, three monoclonal antibodies, two replacement factors, one enzyme and one antisense oligonucleotide.

Growth will be driven by the launch of gene therapies, continuing preference for prophylactic regiments, and an increasing life expectancy for hemophiliacs. The major barriers for growth in the hemophilia A and B market include the possible market access issues for gene therapies due to high upfront costs and declining prevalent cases in certain countries.

Key Highlights

• Growth will be driven by the launch of gene therapies, continuing preference for prophylactic regiments, and an increasing life expectancy for hemophiliacs
• The major barriers for growth in the hemophilia A and B market include the possible market access issues for gene therapies due to high upfront costs and declining prevalent cases in certain countries
• BioMarin’s Roctavian is expected to leapfrog Hemlibra’s sales to become the market leader by the end of the forecast period
• The most important unmet needs in the Hemophilia A and B market include: the development of more curative treatments, more therapies for hemophilia B patients with inhibitors, decreasing the costs of prophylactic treatment, and introducing more therapies with convenient routes of administration

Key Questions Answered

• 11 late-stage pipeline agents are expected to enter the Hemophilia A and B market from 2021 onwards. What impact will these agents have on the market?
• Which of these drugs will have the highest peak sales, and why?
• What are the current unmet needs in Hemophilia A and B, which pipeline agents are positioned to counter these unmet needs?
• What are the opportunities for R&D?
• What is the market outlook in the 8MM from 2020-2030? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
• What are the main corporate trends?
• Who are the current and future players?

Key Topics Covered:

1 Hemophilia A and B: Executive Summary

1.1 The Hemophilia A and B Market Is Expected to Grow to $14.71B by 2030

1.2 Gene Therapies and Alternative Modulators of the Coagulation Cascade Remain the Main R&D Focus

1.3 Unmet Need for Innovative Agents in Different Patient Populations to be Partially Addressed but with Increasing Cost of Therapy

1.4 Gene Therapies to Dominate the Late-Stage Pipeline of Hemophilia A and B

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Sources Not Used

4.4.3 Forecast Assumptions and Methods

4.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

4.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

4.4.6 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status

4.4.7 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

4.4.8 Types of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

4.4.9 Diagnosed Prevalent Cases of Acquired Hemophilia

4.5 Epidemiological Forecast for Hemophilia A (2020-2030)

4.5.1 Diagnosed Prevalent Cases of Hemophilia A

4.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A

4.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A

4.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity

4.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors

4.6 Epidemiological Forecast for Hemophilia A and Hemophilia B (2020-2030)

4.6.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

4.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

4.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

4.6.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

4.6.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors

4.6.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

4.6.7 Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

4.6.8 Diagnosed Prevalent Cases of Acquired Hemophilia

4.7 Discussion

4.7.1 Epidemiological Forecast Insight

4.7.2 COVID-19 Impact

4.7.3 Limitations of the Analysis

4.7.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.1.1 Hemophilia A and B Without Inhibitors

5.1.2 Hemophilia A and B with Inhibitors

5.2 KOL Insights on Disease Management

5.2.1 Hemophilia A and B Without Inhibitors

5.2.2 Hemophilia A and B with Inhibitors

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Development of More Curative Treatments

7.3 Reduction in Risk of Inhibitor Development in Previously Untreated Patients

7.4 More Effective Treatments for Hemophilia B Patients with Inhibitors

7.5 Decreasing the Costs Associated with Prophylaxis

7.6 More Therapies with Convenient Administration Routes

8 R&D Strategies

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

13 Appendix

Companies Mentioned

• Aptevo
• Bayer
• BioMarin
• Catalyst Biosciences
• CSL Behring
• GC Pharma
• Kaifeng Pharmaceutical
• KM Biologics
• LFB
• Novo Nordisk
• Pfizer
• Octapharma
• Roche
• Sanofi
• SinoCelltech
• Spark Therapeutics
• Takeda
• UniQure

For more information about this report visit https://www.researchandmarkets.com/r/4uan3d.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900